Mesothelioma Trial to Test Cancer Vaccine with Immunotherapy
A research team at Oslo University Hospital in Norway has opened a mesothelioma clinical trial using the novel UV1 cancer vaccine alongside a promising immunotherapy combination. UV1 is a peptide-based vaccine designed to induce a specific T-cell response and increase the effectiveness of the immunotherapy drugs. This is the first time UV1 will be studied with mesothelioma cancer, but it already has shown safety and signs of efficacy when used on malignant melanoma, prostate cancer and lung cancer in studies worldwide. It will be used with the immunotherapy combination of nivolumab and ipilimumab, also known by brand names...
Source: Asbestos and Mesothelioma News - September 14, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

Combination immunotherapy benefits subset of patients with advanced prostate cancer
(University of Texas M. D. Anderson Cancer Center) esults from a Phase II trial led by researchers at MD Anderson Cancer Center suggest that a combination of ipilimumab (anti-CTLA-4) plus nivolumab (anti-PD-1) can generate durable responses in a subset of patients with advanced prostate cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 10, 2020 Category: Cancer & Oncology Source Type: news

Immunotherapy Combination Extends Mesothelioma Survival
Standard-of-care treatment for unresectable pleural mesothelioma cancer could be changing soon, sparked by a recently completed international study of a novel immunotherapy combination. Patients in the randomized mesothelioma clinical trial who were treated with ipilimumab (Yervoy) and nivolumab (Opdivo) had a median overall survival of 18.1 months, compared to 14.1 months for those receiving chemotherapy. The results of the mesothelioma trial, which was sponsored by Bristol Myers Squibb, were presented at the recent World Conference on Lung Cancer virtual meeting. Authors of the study said it was the first time an immuno...
Source: Asbestos and Mesothelioma News - August 11, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

Chemo-Free Management of Mesothelioma on Horizon Chemo-Free Management of Mesothelioma on Horizon
Combination immunotherapy with nivolumab and ipilimumab could replace chemotherapy for patients with treatment-naive mesothelioma, suggest new phase 3 trial data.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - August 11, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Nivolumab Plus Ipilimumab or Pembrolizumab Most Cost-Effective for Newly Diagnosed Advanced Melanoma Nivolumab Plus Ipilimumab or Pembrolizumab Most Cost-Effective for Newly Diagnosed Advanced Melanoma
BRAF and MEK inhibitors might be used in a second-line setting after BRAF pathogenic variant is confirmed.Reuters Health Information (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - August 4, 2020 Category: Allergy & Immunology Tags: Hematology-Oncology News Source Type: news

Merck, Targovax Team Up for New Mesothelioma Clinical Trial
Standard-of-care treatment for malignant mesothelioma could change significantly, depending upon the results of an upcoming clinical trial of two immunotherapy agents used in combination with chemotherapy. The mesothelioma clinical trial will involve pembrolizumab, also known by the brand name Keytruda, and its synergy with ONCOS-102, a lesser-known, genetically modified adenovirus. Individually, both have shown modest efficacy for mesothelioma patients when used with chemotherapy. Together, there is potential for a much greater impact in significantly extending patient survival. The clinical trial is a partnership between...
Source: Asbestos and Mesothelioma News - July 22, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

Frontline Nivolumab/Ipilimumab with Limited Chemo Derives OS Benefit in NSCLC
Overall survival (OS) benefit derived from frontline treatment with nivolumab plus ipilimumab combined with 2 cycles of platinum-doublet chemotherapy in patients with metastatic or recurrent non-small cell lung cancer was further improved after at least 12 months of follow-up. (Source: CancerNetwork)
Source: CancerNetwork - May 31, 2020 Category: Cancer & Oncology Authors: Kristie L. Kahl Source Type: news

Nivolumab/Ipilimumab Combo Yields Durable Efficacy in Advanced NSCLC
Frontline treatment with nivolumab plus ipilimumab induced durable and long-term efficacy, compared with chemotherapy, in patients with advanced non-small cell lung cancer, regardless of PD-L1 expression. (Source: CancerNetwork)
Source: CancerNetwork - May 30, 2020 Category: Cancer & Oncology Authors: Kristie L. Kahl Source Type: news

FDA approves nivolumab plus ipilimumab and chemotherapy for first-line treatment of metastatic NSCLC
Hematology / Oncology News Burst (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - May 27, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

FDA Approves Nivolumab Plus Ipilimumab with Chemotherapy for NSCLC
The FDA approved the use of nivolumab plus ipilimumab given with 2 cycles of platinum-doublet chemotherapy as a first-line treatment for adult patients with metastatic or recurrent non-small cell lung cancer. (Source: CancerNetwork)
Source: CancerNetwork - May 27, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

U.S. Food and Drug Administration Approves Opdivo (nivolumab) + Yervoy (ipilimumab) Combined with Limited Chemotherapy as First-Line Treatment of Metastatic or Recurrent Non-Small Cell Lung Cancer
PRINCETON, N.J.--(BUSINESS WIRE) May 26, 2020 --Bristol Myers Squibb (NYSE: BMY) today announced that Opdivo (nivolumab) 360 mg plus Yervoy (ipilimumab) 1 mg/kg (injections for intravenous use) given with two cycles of platinum-doublet chemotherapy... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - May 26, 2020 Category: Drugs & Pharmacology Source Type: news

FDA Approves Opdivo (nivolumab) + Yervoy (ipilimumab) Combined with Limited Chemotherapy as First-Line Treatment of Metastatic or Recurrent Non-Small Cell Lung Cancer
PRINCETON, N.J.--(BUSINESS WIRE) May 26, 2020 --Bristol Myers Squibb (NYSE: BMY) today announced that Opdivo (nivolumab) 360 mg plus Yervoy (ipilimumab) 1 mg/kg (injections for intravenous use) given with two cycles of platinum-doublet chemotherapy... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - May 26, 2020 Category: Drugs & Pharmacology Source Type: news

FDA Approves Chemo-Free Combo for Lung Cancer FDA Approves Chemo-Free Combo for Lung Cancer
The combination of nivolumab plus ipilimumab is now approved as first-line treatment for patients with metastatic non-small-cell lung cancer.FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 16, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

FDA approves nivolumab plus ipilimumab for first-line mNSCLC (PD-L1 tumor expression ≥1%)
Hematology / Oncology News Burst (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - May 15, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

FDA Approves Combination of Nivolumab Plus Ipilimumab for mNSCLC
The FDA approved the combination of nivolumab plus ipilimumab as a first-line treatment for patients with metastatic non-small cell lung cancer whose tumors express PD-L1 ( ≥1%), as determined by an FDA-approved test. (Source: CancerNetwork)
Source: CancerNetwork - May 15, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

U.S. Food and Drug Administration Approves Opdivo (nivolumab) + Yervoy (ipilimumab) as First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer Whose Tumors Express PD-L1 ≥1%
PRINCETON, N.J.--(BUSINESS WIRE) May 15, 2020 --Bristol Myers Squibb (NYSE: BMY) today announced that Opdivo (nivolumab) 3 mg/kg plus Yervoy (ipilimumab) 1 mg/kg (injections for intravenous use) was approved by the U.S. Food and Drug Administration... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - May 15, 2020 Category: Drugs & Pharmacology Source Type: news

Mesothelioma Drug Combination Continues to Show Promise
Pharmaceutical giant Bristol Myers Squibb continues to tout its immunotherapy combination of Opdivo and Yervoy for first-line treatment of patients with pleural mesothelioma cancer. Bristol Myers Squibb recently announced that overall survival “significantly improved” when the combination was measured against standard chemotherapy in a randomized, phase III clinical trial of previously untreated mesothelioma patients. Its announcement was based on a pre-specific interim analysis conducted by the Data Monitoring Committee, a clinical study organization independent of Bristol Myers Squibb. The study is being cond...
Source: Asbestos and Mesothelioma News - May 4, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

CheckMate-743 Trial of Nivolumab, Ipilimumab Meets Primary Endpoint in Mesothelioma Trial
The trial evaluating nivolumab in combination with ipilimumab in previously untreated malignant pleural mesothelioma met its primary endpoint of overall survival. (Source: CancerNetwork)
Source: CancerNetwork - April 21, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

FDA Grants Priority Review to Nivolumab Plus Ipilimumab to Treat NSCLC
Bristol Myers Squibb recently announced that the FDA granted priority review to nivolumab plus ipilimumab in combination with chemotherapy as a first-line treatment for metastatic NSCLC. (Source: CancerNetwork)
Source: CancerNetwork - April 8, 2020 Category: Cancer & Oncology Authors: Matthew Fowler Source Type: news

Patients of Metastatic Prostate Cancer Could Benefit from Immunotherapy Treatment
A recent study found that a group of patients with metastatic castration-resistant prostate cancer responded positively to treatment with ipilimumab, prolonging survival after treatment in the “favorable” cohort. (Source: CancerNetwork)
Source: CancerNetwork - April 7, 2020 Category: Cancer & Oncology Authors: Matthew Fowler Source Type: news

FDA Approves Immunotherapy Combo for Liver Cancer FDA Approves Immunotherapy Combo for Liver Cancer
Nivolumab and ipilimumab together produce a response rate double that of nivolumab alone in advanced hepatocellular carcinoma.FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 11, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

FDA grants accelerated approval to nivolumab and ipilimumab combination for hepatocellular carcinoma
Hematology / Oncology Approvals (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - March 11, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

U.S. Food and Drug Administration approves Opdivo ® (nivolumab) + Yervoy® (ipilimumab) for patients with hepatocellular carcinoma (HCC) previously treated with sorafenib
Bristol Myers Squibb Company (NYSE: BMY) today announced that Opdivo (nivolumab) 1 mg/kg plus Yervoy (ipilimumab) 3 mg/kg (injections for intravenous use) was approved by the U.S. Food and Drug Administration (FDA) to treat hepatocellular carcinoma (HCC) in patients who have been previously treated with sorafenib.1,2 Approval for this indication has been granted under accelerated approval based on (Source: World Pharma News)
Source: World Pharma News - March 11, 2020 Category: Pharmaceuticals Tags: Featured Bristol-Myers Squibb Business and Industry Source Type: news

FDA Approves Nivolumab-Ipilimumab Combo for Hepatocellular Carcinoma
The FDA approved the combination use of nivolumab plus ipilimumab for the treatment of patients with HCC who have been previously treated with sorafenib. (Source: CancerNetwork)
Source: CancerNetwork - March 11, 2020 Category: Cancer & Oncology Authors: Kristie L. Kahl Source Type: news

Some Rare Neuroendocrine Tumors May Respond to Ipilimumab Plus Nivolumab Some Rare Neuroendocrine Tumors May Respond to Ipilimumab Plus Nivolumab
Patients with fast-growing non-pancreatic neuroendocrine tumors may respond to combination therapy with ipilimumab plus nivolumab, according to findings within the Dual Anti-CTLA-4& Anti-PD-1 blockade in Rare Tumors (DART) trial.Reuters Health Information (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - March 5, 2020 Category: Allergy & Immunology Tags: Hematology-Oncology News Source Type: news

Pre-operative immunotherapy triggers encouraging response in oral cancers
(American Society for Radiation Oncology) A new clinical trial suggests that immunotherapy given before other treatments for oral cavity cancers can elicit an immune response that shrinks tumors, which could provide long-term benefit for patients. In the randomized trial, two neoadjuvant doses of nivolumab given with or without ipilimumab led to complete or partial tumor shrinkage in most cases and did not delay any patients from continuing on to standard treatment. Findings will be presented at the 2020 Multidisciplinary Head and Neck Cancers Symposium. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 27, 2020 Category: Cancer & Oncology Source Type: news

Mesothelioma Clinical Trial Involves Immunotherapy Before Surgery
Three of the country’s leading cancer centers have opened a collaborative clinical trial that potentially could change surgical treatment of mesothelioma. Researchers will measure the safety and efficacy of using two different immunotherapy drug regimens — Opdivo (nivolumab) and Yervoy (ipilimumab) — beginning 42 days before surgery. The hope is that at least one will make surgical resection more effective. Sidney Kimmel Cancer Center at Johns Hopkins University, MD Anderson Cancer Center at the University of Texas and Greenebaum Cancer Center at the University of Maryland are working together to enroll a...
Source: Asbestos and Mesothelioma News - February 24, 2020 Category: Environmental Health Authors: Matt Mauney Source Type: news

U.S. Food and Drug Administration accepts for Priority Review Bristol-Myers Squibb's application for Opdivo (nivolumab) plus Yervoy (ipilimumab) in first-line non-small cell lung cancer
Bristol-Myers Squibb Company (NYSE: BMY) announced the U.S. Food and Drug Administration (FDA) has accepted its supplemental Biologics License Application (sBLA) for Opdivo (nivolumab) in combination with Yervoy (ipilimumab) for the first-line treatment of patients with metastatic or recurrent non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumor aberrations. (Source: World Pharma News)
Source: World Pharma News - January 17, 2020 Category: Pharmaceuticals Tags: Featured Bristol-Myers Squibb Business and Industry Source Type: news

FDA Grants Priority Review to Frontline Nivolumab-Ipilimumab Combo for NSCLC
The FDA accepted and granted priority review to the supplemental biologics license application for nivolumab in combination with ipilimumab for the first-line treatment of patients with metastatic or recurrent non-small cell lung cancer. (Source: CancerNetwork)
Source: CancerNetwork - January 15, 2020 Category: Cancer & Oncology Authors: Kristie L. Kahl Source Type: news

Immunotherapy is safe following chemoradiotherapy for women with node-positive cervical cancer
(NRG Oncology) Results from the NRG Oncology phase I clinical trial NRG-GOG 9929 show that utilizing the immunotherapy drug ipilimumab after chemoradiotherapy (CRT) is tolerated in the curative treatment of women with lymph node-positive cervical cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 27, 2019 Category: Cancer & Oncology Source Type: news

Domenico Mallardo, MD, on Anti-CTLA4 Agents in Melanoma
Domenico Mallardo, MD, Istituto Nazionale Tumori " Fondazione Pascale " in Naples, discusses results from his trial – designed to evaluate anti-CTLA4 agents in patients with melanoma who relapsed on treatment with ipilimumab (Yervoy), which was presented at the 34th Annual Meeting& Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019). (Source: CancerNetwork)
Source: CancerNetwork - November 14, 2019 Category: Cancer & Oncology Authors: Domenico Mallardo, MD Source Type: news

FDA Grants Priority Review to Opdivo-Yervoy Combo in Advanced HCC
The FDA has accepted the supplemental biologics license application and granted breakthrough therapy designation to nivolumab plus ipilimumab for the treatment of patients with advanced hepatocellular carcinoma previously treated with sorafenib. (Source: CancerNetwork)
Source: CancerNetwork - November 11, 2019 Category: Cancer & Oncology Authors: Kristie L. Kahl Source Type: news

Bristol-Myers' immunotherapies show promise in lung cancer trial; shares rise
Bristol-Myers Squibb Co said on Tuesday an interim analysis of a late-stage trial testing a combination of its immuno-oncology drugs Opdivo and Yervoy met the main goal of extending life of previously untreated lung cancer patients. (Source: Reuters: Health)
Source: Reuters: Health - October 22, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

Nivolumab Therapy Prolongs Survival in Advanced Melanoma
Overall survival at five years longer with nivolumab + ipilimumab, nivolumab alone versus ipilimumab (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - September 30, 2019 Category: Cancer & Oncology Tags: Dermatology, Oncology, Pharmacy, Conference News, Source Type: news

Nivolumab Therapy Prolongs Survival in Advanced Melanoma
MONDAY, Sept. 30, 2019 -- More patients with advanced melanoma receiving nivolumab plus ipilimumab or nivolumab alone have sustained long-term survival at five years compared with those receiving ipilimumab alone, according to a study published... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 30, 2019 Category: Pharmaceuticals Source Type: news

Could All Patients With Advanced NSCLC Go Chemo-Free? Could All Patients With Advanced NSCLC Go Chemo-Free?
Results from CheckMate 227 suggest that combination nivolumab and ipilimumab may eliminate the need for chemotherapy in advanced NSCLC, regardless of PD-L1 status.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 28, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

One in Two Patients With Metastatic Melanoma Alive After 5 Years One in Two Patients With Metastatic Melanoma Alive After 5 Years
With the combination of ipilimumab and nivolumab, 50% of patients are still alive after 5 years, a survival rate remarkably higher than that seen with either agent alone.Medscape Medical News (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - September 28, 2019 Category: Pathology Tags: Hematology-Oncology News Source Type: news

Bristol-Myers immunotherapy combo outperforms chemo in lung cancer survival: study
About 40% of patients who received a combination of Bristol-Myers Squibb Co's immuno-oncology drugs Opdivo and Yervoy as an initial treatment for advanced non-small cell lung cancer (NSCLC) were alive after two years, according to data presented at a medical meeting on Saturday. (Source: Reuters: Health)
Source: Reuters: Health - September 28, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

The Kidney Cancer Association Announces Recipients for the Advanced Discovery Awards (ADA) and Young Investigator Awards (YIA)
A total of $1.3 million awarded to advance new treatments for kidney cancerHOUSTON– September 16, 2019– The Kidney Cancer Association (KCA) is pleased to announce the recipients of the Advanced Discovery Awards (ADA) and Young Investigator Awards (YIA). In April, the KCA approved $1.3 million in new grant funding to advance early detection and new treatments for kidney cancer. “The KCA was delighted by the high caliber of proposals received for both awards and are hopeful that this research will advance the medical community’s understanding of kidney cancer,” said Dr. Christopher Wood, Ch...
Source: Kidney Cancer Association - September 16, 2019 Category: Urology & Nephrology Source Type: news

Evaluating the Safety of Immunotherapy in NSCLC Patients With Comorbidities
Combination immunotherapy with nivolumab plus ipilimumab was examined as a first-line therapy for patients with  advanced non–small-cell lung cancer. Results were presented at the International Associate for the Study of Lung Cancer 2019 World Conference on Lung Cancer. (Source: CancerNetwork)
Source: CancerNetwork - September 10, 2019 Category: Cancer & Oncology Authors: Naveed Saleh, MD, MS Source Type: news

CheckMate 204 Update: Practice-Changing for Brain Metastases? CheckMate 204 Update: Practice-Changing for Brain Metastases?
New data show that ipilimumab plus nivolumab can produce a long-term response in patients with melanoma and brain metastases, says Dr Jeffrey Weber.Medscape Oncology (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - September 9, 2019 Category: Radiology Tags: Hematology-Oncology Commentary Source Type: news

Nivolumab Plus Ipilimumab Beats Sunitinib for Advanced Kidney Cancer Nivolumab Plus Ipilimumab Beats Sunitinib for Advanced Kidney Cancer
Nivolumab plus ipilimumab is more effective than sunitinib as first-line treatment for patients with advanced renal-cell carcinoma (RCC), according to an extended follow-up of the ongoing CheckMate 214 trial.Reuters Health Information (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - September 3, 2019 Category: Allergy & Immunology Tags: Hematology-Oncology News Source Type: news

Creating a Patient Trial Community
When TJ Sharpe was diagnosed with Stage 4 melanoma in August 2012, his future looked bleak. He was 37 years old with two young children, the median lifespan for patients with his diagnosis was 18 months and treatment options were limited.Thanks to some knowledge of the pharmaceutical industry he soon realised his best chance of survival was to find a clinical trial. It was a daunting prospect, but his resolve was solid and, after undergoing six surgical operations and four immunotherapy treatments across two different clinical trials, he lived to tell the tale.“I was lucky,” says Sharpe, “I was aware of c...
Source: EyeForPharma - August 13, 2019 Category: Pharmaceuticals Authors: Katie Osborne Source Type: news

Creating a Patient Trial Community
When TJ Sharpe was diagnosed with Stage 4 melanoma in August 2012, his future looked bleak. He was 37 years old with two young children, the median lifespan for patients with his diagnosis was 18 months and treatment options were limited.Thanks to some knowledge of the pharmaceutical industry he soon realised his best chance of survival was to find a clinical trial. It was a daunting prospect, but his resolve was solid and, after undergoing six surgical operations and four immunotherapy treatments across two different clinical trials, he lived to tell the tale.“I was lucky,” says Sharpe, “I was aware of c...
Source: EyeForPharma - August 13, 2019 Category: Pharmaceuticals Authors: Katie Osborne Source Type: news

Creating a Patient Trial Community
When TJ Sharpe was diagnosed with Stage 4 melanoma in August 2012, his future looked bleak. He was 37 years old with two young children, the median lifespan for patients with his diagnosis was 18 months and treatment options were limited.Thanks to some knowledge of the pharmaceutical industry he soon realised his best chance of survival was to find a clinical trial. It was a daunting prospect, but his resolve was solid and, after undergoing six surgical operations and four immunotherapy treatments across two different clinical trials, he lived to tell the tale.“I was lucky,” says Sharpe, “I was aware of c...
Source: EyeForPharma - August 13, 2019 Category: Pharmaceuticals Authors: Katie Osborne Source Type: news

Bristol-Myers releases mixed Opdivo lung cancer results
Bristol-Myers Squibb Co released mixed results on Wednesday from trials testing the survival benefit of its immunotherapy Opdivo in combination with either chemotherapy or its other immuno-oncology drug, Yervoy, as an initial treatment for advanced lung cancer. (Source: Reuters: Health)
Source: Reuters: Health - July 24, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

ipilimumab (Yervoy)
Title: ipilimumab (Yervoy)Category: MedicationsCreated: 6/21/2019 12:00:00 AMLast Editorial Review: 6/21/2019 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - June 21, 2019 Category: Drugs & Pharmacology Source Type: news

Dr. Hussein Tawbi on Efficacy and Safety Results From the CheckMate 204 Melanoma Trial
Cancer Network spoke with Hussein Tawbi, MD, PhD, of MD Anderson Cancer Center, about the efficacy and safety of the combination of nivolumab plus ipilimumab in patients with symptomatic melanoma brain metastases. (Source: CancerNetwork)
Source: CancerNetwork - June 19, 2019 Category: Cancer & Oncology Authors: Hussein Abdul-Hassan Tawbi, MD, PhD Source Type: news

Dr. Ahmad Tarhini on Ipilimumab vs Interferon- α2b for Resected High-Risk Melanoma
Cancer Network spoke with Ahmad Tarhini, MD, PhD, about the results of the phase III  United States Intergroup E1609 trial, presented at ASCO 2019. (Source: CancerNetwork)
Source: CancerNetwork - June 12, 2019 Category: Cancer & Oncology Authors: Ahmad A. Tarhini, MD, PhD Source Type: news

Do Brain Metastases Rule Out Immunotherapy in RCC?
An interim analysis of the CheckMate 920 phase IIIb/IV trial evaluated nivolumab plus ipilimumab in advanced renal cell carcinoma patients with brain metastases. (Source: CancerNetwork)
Source: CancerNetwork - June 11, 2019 Category: Cancer & Oncology Authors: Jim Kling Source Type: news